GlassScriptPhysician profile
Mark R Anderson
NPI 1346289055
$1,683.89
in general payments reported to CMS, 2019-2025
24 companies · $456 in 2025
The $456 reported for 2025 was more than what 92% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $74.63 · 2021: $236 · 2022: $315 · 2023: $106 · 2024: $358 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912 · Education: $7.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.27 |
| Education | $7.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $414.48 | 2022-2025 | Altrua 20, Synergy, Advantio |
| W. L. Gore & Associates, INC. | $181.64 | 2024 | Gore Cardioform Septal Occluder |
| Hyperfine Operations, INC. | $173.69 | 2025 | Swoop |
| Shockwave Medical, INC | $132.28 | 2025 | |
| Cepheid | $89.82 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.87 | 2021-2022 | |
| Amgen INC. | $69.20 | 2020-2022 | |
| Lilly USA, LLC | $66.46 | 2022 | |
| Astellas Pharma US INC | $58.96 | 2021-2022 | |
| Biogen, INC. | $56.75 | 2020 | |
| Novartis Pharmaceuticals Corporation | $48.81 | 2019 | |
| Upsher-Smith Laboratories LLC | $45.40 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.79 | 2021-2022 | |
| Amarin Pharma, INC. | $40.02 | 2021-2022 | |
| Dexcom, INC. | $39.18 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beckman Coulter, INC. | $25.44 | 2022 | |
| Janssen Pharmaceuticals, INC | $23.92 | 2021 | |
| Novo Nordisk INC | $22.96 | 2022 | |
| Ironshore Pharmaceuticals INC. | $16.17 | 2024 | |
| Abbvie INC. | $14.43 | 2021 | |
| Genzyme Corporation | $13.85 | 2024 | |
| Abbott Laboratories | $12.82 | 2021 | |
| Genentech USA, INC. | $12.73 | 2021 | |
| Btg International INC. | $7.22 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.